Articles tagged with: Pomalyst


[ by | Jun 14, 2014 9:59 pm | One Comment ]
ASCO 2014 Multiple Myeloma Update – Day Four: Poster Presentations

This year’s American Society of Clinical Oncology (ASCO) annual meeting in Chicago ended last Tuesday.

The day before the meeting ended was the busiest day at the meeting with re­gard to myeloma research.  It featured a session of oral pre­sen­ta­tions in the morn­ing and a poster session in the afternoon. In addition, an education ses­sion was held in the afternoon that included one myeloma-related talk, given by Dr. Leif Bergsagel of the Mayo Clinic, about progress in the treatment of mul­ti­ple myeloma (article in the ASCO 2014 Edu­ca­tional Book). …

Read the full story »

News, Opinion»

[ by | Apr 24, 2014 8:27 am | 9 Comments ]
The Myeloma Quiz - April 2014

The Beacon is pleased to introduce our newest myeloma thought leader col­um­nist, Dr. Ravi Vij. Every three months, Dr. Vij will share with us a new edition of “The Myeloma Quiz,” which will test your knowledge and under­standing of the myeloma-related research published during the pre­vi­ous several months.

We hope you will join us in welcoming Dr. Vij to the Beacon community, and in thank­ing him for sharing with us his valuable perspectives.

The relentless grind in the battle against myeloma continues. The last several months have seen some …

Read the full story »


[ by | Mar 1, 2014 5:56 pm | 2 Comments ]
The Top Myeloma Research Of 2013

The year 2013 is likely to be remembered as a very good year when it comes to research related to multiple myeloma.

Previous years have witnessed research shedding new light on existing my­e­lo­ma therapies, as well as additional research about potential new therapies.

But, in the past, most of the important new therapies that were being researched were from existing classes of therapy, making them less likely to offer dramatic im­prove­ments in the treat­ment of the disease.

In 2013, not only was there more research about existing therapies, and more …

Read the full story »


[ by | Feb 11, 2014 1:22 pm | One Comment ]
Pomalyst Approved In Canada For Relapsed And Refractory Multiple Myeloma

Pomalyst is now approved in Canada for the treatment of certain patients with multiple myeloma.

Specifically, Health Canada approved Pomalyst (pomalidomide, Imnovid) for use in combination with dex­a­meth­a­sone (Decadron) in patients with multiple myeloma for whom both Revlimid (lenalidomide) and Velcade (bor­tezomib) have failed, who have received at least two prior treatment regimens, and who have demon­strat­ed disease progression on their last therapy.

Health Canada approved Pomalyst on January 20, but the approval was first announced this morning.

Celgene (NASDAQ: CELG), the company that developed and markets Pomalyst, …

Read the full story »


[ by | Feb 10, 2014 3:38 pm | 4 Comments ]
Pomalyst-Based Combination Regimens Presented At ASH 2013

At the 2013 annual meeting of the American Society of Hematology (ASH), which took place in December, there were many oral and poster pre­sen­ta­tions about Pomalyst, the newest drug approved in the United States and Europe for the treatment of multiple myeloma.

Many of the presentations were about studies of Pomalyst (poma­lido­mide, Imnovid) and dex­a­meth­a­sone (Decadron) in combination with a third drug, such as Velcade (bortezomib), Kyprolis (car­filz­o­mib), cla­rith­ro­my­cin (Biaxin), cyclo­phos­pha­mide (Cytoxan), or Doxil (doxorubicin lipo­somal), for relapsed and refractory myeloma. …

Read the full story »